Extended release dipyridamole 200mg/aspirin 25mg ( DrugBank: Aspirin, Dipyridamole )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01781611 (ClinicalTrials.gov) | February 2013 | 2/1/2013 | Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) | Dipyridamole Assessment for Flare Reduction in SLE | Systemic Lupus Erythematosus | Drug: extended release dipyridamole 200mg/aspirin 25mg;Drug: 81mg aspirin | Oklahoma Medical Research Foundation | NULL | Terminated | 18 Years | 70 Years | All | 18 | N/A | United States |